Genotypic and phenotypic cross-drug resistance of harboring drug-Resistant HIV type 1 subtype B′ strains from former blood donors in central Chinese provinces

AIDS Research and Human Retroviruses

Volumn 26, Issue 9, 2010, Pages 1007-1013

  Ma, Liying ^a   Huang, Jianghong ^a   Xing, Hui ^a   Yuan, Lin ^a   Yu, Xiaoling ^a,b   Sun, Jianping ^a   Huang, Yang ^a   Qu, Shuiling ^a   Feng, Yi ^a   Liao, Linjie ^a   Liu, Shuwen ^b   Shao, Yiming ^a  

^a CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; THYMIDINE DERIVATIVE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; POL PROTEIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL RESISTANCE; ARTICLE; BLOOD DONOR; CHINA; CHINESE; CROSS RESISTANCE; FEMALE; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS STRAIN; DRUG EFFECTS; GENETICS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MIDDLE AGED; MULTIDRUG RESISTANCE; MUTATION; SEQUENCE ANALYSIS;

ADULT; ANTI-HIV AGENTS; BLOOD DONORS; CHINA; DIDANOSINE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MUTATION; PHENOTYPE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; STAVUDINE; ZIDOVUDINE;

EID: 77956372191     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0252     Document Type: Article

References (23)

1. Wu Z, Liu Z, and Detels R: HIV-1 infection in commercial plasma donors in China. Lancet 1995;346:61-62.
2. He N and Detels R: The HIV epidemic in China: History, response, and challenge. Cell Res 2005;15:825-832.
3. Zhang F, Dou Z, Yu L, et al.: The effect of highly active antiretroviral therapy on mortality among HIV-infected former plasma donors in China. Clin Infect Dis 2008;47: 825-833.
4. hao Y: AIDS epidemic at age 25 and control efforts in China. Retrovirology 2006;3:87.
5. DeGruttola V, Dix L, DAquila R, et al.: The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther 2000; 5:41-48.
6. Haubrich R and Demeter L: International perspectives on antiretroviral resistance. Clinical utility of resistance testing: Retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr 2001;26(Suppl 1):S51-59.
7. Li JY, Li HP, Li L, et al.: Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res 2005;15:843-849.
8. Zhang M, Han XY, Cui WG, et al.: The impact of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation. Jpn J Infect Dis 2008;61:361-365.
9. Peeters M, Liegeois F, Torimiro N, et al.: Characterization of a highly replicative intergroup M/O human immunodeficiency virus type 1 recombinant isolated from a Cameroonian patient. J Virol 1999;73:7368-7375.
10. Platt EJ, Wehrly K, Kuhmann SE, et al.: Effects of CCR5 and CD4cell surface concentrations on infections by macrophage-tropic isolates of human immunodeficiency virus type 1. J Virol 1998;72:2855-2864.
11. Ma L, Sun J, Xing H, et al.: Genotype and phenotype patterns of drug-resistant HIV-1 subtype B (Thai B) isolated from patients failing antiretroviral therapy in China. J Acquir Immune Defic Syndr 2007;44:14-19.
12. Bulgheroni E, Croce F, Citterio P, et al.: Unusual codon 69 insertions: influence on human immunodeficiency virus type 1 reverse transcriptase drug susceptibility. J Clin Virol 2004;29:27-32.
13. Minuesa G, Volk C, Gorboulev V, et al.: Identification of lamivudine (3TC) as a novel substrate for human organic cation transporters 1, 2 and 3. Antiviral Ther 2008;13:A59 (Abstract No. 54).
14. armati L, Nicastri E, Parisi SG, et al.: Discordance between genotypic and phenotypic drug resistance profiles in human immunodeficiency virus type 1 strains isolated from peripheral blood mononuclear cells. J Clin Microbiol 2002;40: 335-340.
15. Hanna GJ and DAquila RT: Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001;32:774-782.
16. Kumar S, Nei M, Dudley J, et al.: MEGA: A biologist-centric software for evolutionary analysis of DNA and protein sequences. Brief Bioinform 2008;9:299-306.
17. Johnson VA, Brun-Vezinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16:138-145.
18. Ma L, Guo Y, Yuan L, et al.: Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07-BC strains circulating in the Xinjiang province of China. Retrovirology 2009;6:45.
19. Shafer RW and Schapiro JM: HIV-1 drug resistance mutations: An updated framework for the second decade of HAART. AIDS Rev 2008;10(2):67-84.
20. DHHS: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Available at http://aidsinfor.nih.gov. Accessed May 18, 2006.
21. Wools-Kaloustian K, Kimaiyo S, Diero L, et al.: Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: Experience from western Kenya. AIDS 2006; 20:41-48.
22. Geretti AM: Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis 2007; 20:22-32.
23. Droz C, Morand-Joubert L, and Raguin G: Impact and evolution of resistance in patients treated by a salvage regimen combining amprenavir, lopinavir and ritonavir (the puzzle 1 study). Antiviral Ther 2002;7:S111.